Helmholtz Gemeinschaft

Search
Browse
Statistics
Feeds

Radiosensitisation of U87MG brain tumours by anti-epidermal growth factor receptor monoclonal antibodies

Item Type:Article
Title:Radiosensitisation of U87MG brain tumours by anti-epidermal growth factor receptor monoclonal antibodies
Creators Name:Diaz Miqueli, A. and Rolff, J. and Lemm, M. and Fichtner, I. and Perez, R. and Montero, E.
Abstract:As epidermal growth factor receptor (EGFR) has been reported to be a radiation response modulator, HER inhibitors are regarded to act as potential radiosensitisers. Our study examined the role of nimotuzumab and cetuximab both, the two monoclonal antibodies (mAbs) to EGFR, as radiosensitisers in a murine glioma model in vivo. Co-administration of both the antibodies with radiation increased the radiosensitivity of U87MG, resulting in a significant delay of subcutaneous (s.c.) tumour growth. Furthermore, the addition of antibodies to the radiation decreased brain tumour sizes and is inhibited by 40-80% the increased tumour cell invasion provoked by radiotherapy, although promoted tumour cell apoptosis. Whereas nimotuzumab led to a reduction in the size of tumour blood vessels and proliferating cells in s.c. tumours, cetuximab had no significant antiangiogenic nor antiproliferative activity. In contrast, cetuximab induced a more marked inhibition of EGFR downstream signalling compared with nimotuzumab. Moreover, both antibodies reduced the total number of radioresistant CD133+ cancer stem cells (CSCs). These results were encouraging, and showed the superiority of combined treatment of mAbs to EGFR and radiation over each single therapy against glioblastoma multiforme (GBM), confirming the role of these drugs as radiosensitisers in human GBM. In addition, we first showed the ability of mAb specifics against EGFR to target radioresistant glioma CSC, supporting the potential use in patients.
Keywords:CD133, Cetuximab, Epidermal Growth Factor Receptor, Glioblastoma Multiforme, Nimotuzumab, Radiation, Animals, Mice
Source:British Journal of Cancer
ISSN:0007-0920
Publisher:Nature Publishing Group (U.K.)
Volume:100
Number:6
Page Range:950-958
Date:24 March 2009
Official Publication:https://doi.org/10.1038/sj.bjc.6604943
PubMed:View item in PubMed

Repository Staff Only: item control page

Open Access
MDC Library